Vermillion announced this week the launch of its new clinical reference laboratory, Aspira Labs.

Scheduled to open next month, the lab provides Vermillion with an in-house facility for running its OVA1 ovarian cancer test, allowing it to end its reliance on Quest Diagnostics, which has previously run all OVA1 tests under the two firms' licensing agreement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.